Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of BAT8008 + BAT1308 with or without BAT4706 in advanced solid tumors
CTR20251857Phase 2Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BAT8008, BAT1308, BAT-4706 in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by Bio-Thera Solutions, Ltd.. Started Jul 2025; status: active.
02
Drugs
BAT8008BAT1308BAT-4706
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251857.